Today brings news of a major win for gene therapies
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the investigational gene therapy DB-OTO improved hearing to normal levels in one child (dosed at 11 months of age) within 24 weeks, and initial hearing improvements were observed in a second child (dosed at 4 years of age) at a 6-week assessment. Both children were born with profound genetic deafness due to variants of the otoferlin gene...Naturally, these wingnuts never ask the obvious question: "If God is perfect how did he screw up these kids?" Or does s/he just get jollies from making some number of humans at least miserable?
No comments:
Post a Comment